AAO 2023: Analysis of pegcetacoplan for cost-effective treatment of geographic atrophy

News
Article

Investigators sought to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA

A person in a white lab coat sits with a computer and a calculator at hand.  Image credit: ©everythingpossible – stock.adobe.com

The study showed that every-other-month treatment was more cost-effective than monthly treatment, investigators reported. Image credit: ©everythingpossible – stock.adobe.com

Reviewed by Nimesh A. Patel, MD

Pegcetacoplan injection (Syfovre, Apellis Pharmaceuticals, Inc.) is the first intravitreal therapy approved by the FDA to treat geographic atrophy (GA). However, because there is no gain in vision associated with the treatment, lead study author Nimesh A. Patel, MD pointed out the need for novel utility metrics.

Patel, from the Department of Ophthalmology, Massachusetts Eye and Ear, Boston, described the study at the American Academy of Ophthalmology annual meeting in San Francisco, California. He collaborated with investigators from the Bascom Palmer Eye Institute, Miami, Florida, and Vitreoretinal Consultants of New York, Great Neck, New York, both in the United States.

The purpose of this investigation was 2-fold: to estimate the costs of treating GA with pegcetacoplan and to identify possible utility measures to compare treatments for GA.

Patel explained that the investigation was modeled on the 2-year data from the DERBY and OAKS studies, the costs were based on Medicare allowables and the assumed costs for treating choroidal neovascular membranes. In addition, the lifetime model was based on the life expectancies of the study population, the rate of GA loss was based on 2-year data, and the upper limit of GA was defined as the total area of the macula.

Analysis results

The results showed that the 2-year cost per RPE cell saved versus sham was $8.43 and every month and $4.86 for every other month. The marginal cost, ie, every month compared with every other month, per RPE cell saved was $30. The cost per area of RPE saved in the extrafoveal group was $53,900/mm2 for every month treatment and $32,100/mm2 for every other month treatment, Patel reported.

The lifetime model indicated that the time to when the GA involved 95% of the macula was 14.0 years with monthly treatment, 13.6 years with every other month treatment, and 11 years for sham treatment.

Regarding the lifetime cost per area, the analysis showed that the costs per quality adjusted life year gained based on the modeled visual loss with 95% atrophy were $643,000 with monthly treatment and $372,000 with every other month treatment.

A photo of Nimesh A. Patel, MD.

Image courtesy of Nimesh A. Patel, MD

The investigators concluded that the study defined novel metrics of effectiveness and utility for GA as the cost/area of GA saved and the cost per retinal pigment epithelial (RPE) cell. The study also showed that every-other-month treatment was more cost-effective than monthly treatment and that treatment of extrafoveal lesions was more cost effective than treating all lesions.

“There is a significant cost to treating GA and these metrics will help to determine which treatments are most cost-effective as other options become available,” Patel concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.